How do you keep a competitive landscape from going stale?
How do I keep a current, subtype-level read on my competitive landscape without commissioning a quarter-long report every time?
Competitive landscapes change continuously, but landscape reports are commissioned in quarters and age before they're read. We used Hydra to build a queryable, subtype-level view, efficacy (TNBC, PD-L1+, and more), safety, and trial design across agents, that re-runs against new readouts in hours instead of expiring as a static deck.
Who this is for: Competitive-intelligence, strategy, and search-and-evaluation teams tracking a moving therapeutic landscape.
- efficacy resolved per subtype, not per drug
- subtype-level
- both extracted into one comparable view
- efficacy + safety
- refreshes on new readouts vs a one-off report
- re-runnable
efficacy resolved per subtype, not per drug
both extracted into one comparable view
refreshes on new readouts vs a one-off report
Why quarterly competitive reviews go stale
A therapeutic landscape changes continuously, new readouts, new entrants, shifting safety signals, but competitive analyses are commissioned in quarters. By the time a deep landscape report lands, parts of it are already out of date, and re-running it for a new question means starting over from scratch.
Strategy and search-and-evaluation teams don't want a static deck; they want to ask specific questions, who leads in this subtype, where is our pipeline exposed, and get a current, evidenced answer they can defend in front of an executive team.
What teams in this space search for
- How do I keep my competitive landscape up to date?
- Which drug leads in which cancer subtype?
- Where is my pipeline exposed competitively?
How we solved it with Hydra
“Build a queryable competitive landscape for this therapeutic area. For each agent, give me efficacy by subtype, safety profile, and trial design, all source-linked. Keep it re-runnable so I can refresh it against new readouts and ask follow-up questions like who leads in a given subtype or where our pipeline is exposed.”
What Hydra ran
Hydra assembled the landscape from public sources and kept it queryable, using the same subtype-level efficacy-and-safety extraction as the combination-safety work, so each agent carries efficacy by subtype (TNBC, PD-L1-positive, and so on), a safety profile, and how its trials are designed and enriched.
Because the analysis is generated rather than hand-built, it re-runs against new data or a new question without restarting, and every claim links back to its source.
What it found
The output is a living view rather than a snapshot: ask a new question, point it at new readouts, or change the competitive set, and it updates, no fresh manual project. Every comparison traces to a trial or publication, so it survives the scrutiny of an executive review.
What we learned
The difference is repeatability: a traditional landscape report is a snapshot, while a generated analysis is a function you can re-run. That turns competitive intelligence from a periodic deliverable into an always-available capability.
Monitoring isn't a dead end either, the same subtype-level reads feed combination-safety scoring and route low-response subpopulations into target discovery, so competitive intelligence becomes an input to the rest of the pipeline.
What you get
- A queryable competitive picture that refreshes instead of expiring
- Efficacy-by-subtype and safety comparisons in one transparent view
- Answers to specific strategic questions in hours, not a quarter
- Source-traceable claims that hold up in executive review
Data sources used
- ClinicalTrials.gov (trials, design, enrichment)
- Published trial outcomes (efficacy & safety)
- cBioPortal / TCGA (subtype & biomarker context)
Figures reflect analyses PharosBio ran on public datasets and public benchmarks. Named competitors, collaborators, and logos are withheld at this stage; the methods and results shown are real and repointable to your own target.
Sources & methods
- Landscape & outcomes: ClinicalTrials.gov; published trial outcomes
- Subtype & biomarker context, cBioPortal / TCGA
Frequently asked questions
How is this different from a commissioned landscape report?
A commissioned report is a one-off snapshot that ages immediately. Hydra generates the analysis from public data, so it re-runs against new readouts or new questions, turning a quarterly deliverable into a continuously refreshable, subtype-level view.
Can it answer a specific strategic question?
Yes, it's built to. Rather than one fixed deck, it answers targeted questions like which agent leads in a subtype or where a pipeline is exposed, each with source-linked evidence attached.
Run this analysis on your question
Hydra plans, executes, and validates, so you reach a defensible answer in hours, not weeks.